#USA #Atlanta #UCB #BIMZELX #Hidradenitis Suppurativa

Summary of BIMZELX® Efficacy Over Three Years

Recent three-year data from the BE HEARD trials highlight the effectiveness and tolerability of BIMZELX® (bimekizumab-bkzx) for individuals suffering from moderate-to-severe hidradenitis suppurativa (HS). Conducted by UCB, a leading biopharmaceutical company, this study represents a significant advancement in chronic inflammatory condition management, showcasing sustained symptom relief over multiple clinical indicators.

Sustained Improvements Over Time

The impressive results reveal a high percentage of patients retaining improvements in key clinical endpoints. The stringent scores, namely HiSCR75, HiSCR90, and HiSCR100, demonstrated sustained symptom relief to the percentages of 81.2%, 64.3%, and 50.1% respectively, up to three years after treatment initiation. This data marks a pivotal moment as maintaining symptom relief at these levels is critical for patients' long-term health outcomes and quality of life.

Among the subjects, an astonishing 64.3% maintained total resolution of inflammatory lesions two years after achieving the IHS4-100 metric, a widely recognized European assessment scale for assessing the severity of HS. Furthermore, patients who began treatment earlier in the diagnosis exhibited significantly better outcomes over the two-year follow-up period.

Quality of Life Impact

The quality-of-life assessments also reflected positive trends, with 38.1% of treated patients showing no effects from skin disease after three years, compared to 27.4% achieving this milestone at one year. This improvement can drastically alter daily life and self-perception for those afflicted with HS, who often face debilitating pain and discomfort.

Treatment Efficacy and Safety

BIMZELX has been identified as the first and only approved medication to selectively inhibit Interleukin 17A (IL-17A) and Interleukin 17F (IL-17F), both prominent cytokines involved in inflammatory processes. The treatment has consistently shown a favorable safety profile, with no new safety signals arising in the three-year data, affirming its tolerability across a diverse patient population.

Professor John Ingram from Cardiff University expressed that achieving long-term disease control and mitigating symptoms to the most stringent levels is a fundamental aspect of treating HS. The data supporting bimekizumab affirms that significant symptom relief can indeed be maintained over an extended period, reinforcing its role as a transformative therapy.

Conclusion

As UCB prepares to present these findings at the European Academy of Dermatology and Venereology (EADV) 2025 Congress, the results signify a beacon of hope for individuals battling hidradenitis suppurativa. The comprehensive efficacy data honours UCB's commitment to advancing innovative treatments and bettering patient outcomes, demonstrating the critical nature of continued research and development in this domain. The endurance of symptom relief and improvement in patients' quality of life promises to substantially alter the landscape for managing chronic conditions like HS.